PPLPHARMA

Piramal Pharma Limited

Source: NSE · Updated 4 Nov, 06:28 pm IST

Filed 27 Oct, 09:14 pm IST Q2 FY27 (Sep ’26)Consolidated₹ crores

Revenue

2,617.06

▲ 28.1% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

348.74

▲ 119.8% vs Q2 FY26

Net profit

5.03

vs Q2 FY26: n/a

EPS (₹)

0.04

vs Q2 FY26: n/a

Operating margin

13.3%

+550 bps vs Q2 FY26

Net margin

0.2%

+510 bps vs Q2 FY26

Turned profitable vs Q2 FY26

Revenue+28% vs Q2 FY26 · +15% vs Q1 FY27

ProfitTurned profitable vs Q2 FY26 · Turned profitable vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals.

Previous-quarter and year-ago figures: as originally reported in those quarters' NSE filings; filing PDF not available to confirm restatements.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	2,617.06	2,269.92	▲ 15.3%	2,043.72	▲ 28.1%
Other income	35.93	89.41	▼ 59.8%	65.6	▼ 45.2%
Total income	2,652.99	2,359.33	▲ 12.4%	2,109.32	▲ 25.8%
Total expenses	2,589.1	2,386.35	▲ 8.5%	2,170.29	▲ 19.3%
Operating profit (EBITDA)*	348.74	195.2	▲ 78.7%	158.69	▲ 119.8%
Profit before tax	63.89	-27.02	—	-60.97	—
Tax expense	76.6	61.93	▲ 23.7%	53.04	▲ 44.4%
Net profit	5.03	-69.39	—	-99.22	—
EPS (₹)	0.04	-0.52	—	-0.75	—
Operating margin	13.3%	8.6%	+470 bps	7.8%	+550 bps
Net margin	0.2%	-3.1%	+330 bps	-4.9%	+510 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ crores except EPS. Consolidated figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All Piramal Pharma results, dividends & filings ›

Other results filed 27 Oct

ROUTE ROUTE MOBILE LIMITED›VISL Vedanta Iron and Steel Limited›INDIAMART Indiamart Intermesh Limited›UNIMECH Unimech Aerospace and Manufacturing Limited›LTFOODS LT Foods Limited›QUICKHEAL Quick Heal Technologies Limited›KNACK Knack Packaging Limited›UBL United Breweries Limited›STARHEALTH Star Health and Allied Insurance Company Limited›CGCL Capri Global Capital Limited›SYNGENE Syngene International Limited›CENTENKA Century Enka Limited›

Today's results ›

PIRAMAL PHARMA Q2 FY27 ; NET PROFIT AT ₹5.03 CR VS LOSS ₹99 CR (YOY), LOSS ₹69 CR (QOQ)

REVENUE UP 28% AT ₹2,617 CR (YOY), UP 15% (QOQ)

EBITDA UP 120% AT ₹349 CR (YOY), UP 79% (QOQ)

MARGINS AT 13.3% VS 7.8% (YOY), 8.6% (QOQ)

https://resultkal.com/r/pplpharma-2026-10-27
Source: NSE filing · not investment advice

FAQ

When did Piramal Pharma announce Q2 FY27 results?

Piramal Pharma filed its results on NSE on 27 Oct, 09:14 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these Piramal Pharma figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← PPLPHARMA overview